The Sickle Cell Clinical Trials Network: One Year In
The Hematologist Editor-in-Chief, Dr. Laura Michaelis, spoke with Drs. Charles Abrams and Sophie Lanzkron about a groundbreaking ASH initiative started approximate
Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?
Dr. Kahl studies the biologic underpinnings of a new entity that does not meet the classical definition of double-hit (DH) DLBCL but has gene expression signatures and clin
Insightful critiques and informed commentary of important ongoing clinical trials
Drs. Moll and Nagler discuss the CARAVAGGIO study, an ongoing trial that looks at whether apixaban can be safely and effectively used in patients with cancer and acute deep vein thrombosis or pulmonary embolism.
Dr. DeZern comments on a study in which adult patients with FLT3/ITD acute myeloid leukemia are randomized to receive gilteritinib or placebo after the time of engraftment for a two-year period.
Dr. Fenske and Dr. Kahl discuss a trial enrolling adult patients with mantle cell lymphoma (MCL), who are considered candidates for autologous hematopoietic cell transplantation, to find whether MRD status can be used to personalize therapy in MCL.
Dr. Jacobson reviews a study investigating the safety and efficacy of the anti-CD79b antibody drug conjugate, polatuzumab, in combination with R-CHP versus R-CHOP in previously untreated patients with DLBCL.
Dr. Ding and Dr. Teachey cover a trial that looks at the safety and efficacy of combining the JAK1/JAK2 inhibitor ruxolitinib with post-induction chemotherapy for pediatric patients with Philadelphia chromosome-like B-cell acute lymphoblastic leukemia.
Dr. Linkins discusses the VERDICT Trial which compares reduced doses of apixaban and rivaroxaban with standard-of-care in adult patients with symptomatic proximal deep vein thrombosis or pulmonary embolism and moderate or severe renal insufficiency.
Drs. Luskin, DeAngelo, and Kim review a study that tests the clinical efficacy of combining an adolescent and young adult chemotherapy regimen with a novel antibody in the treatment of B-cell acute lymphoblastic leukemia.
Dr. DeBaun reviews a study that looks at outcomes for pregnant women with sickle cell disease who are randomly assigned to home-based oxygen therapy versus no home-based oxygen therapy.
Dr. Michaelis discusses a study that adds antibody therapy to a reduced-intensity conditioning regimen and protocol-specific allogeneic hematopoietic stem cell transplantation for patients with relapsed or refractory AML over the age of 55.
Drs. Sklavenitis Pistofidis and Ghobrial discuss a study that looks at a targeted approach to therapy for multiple myeloma patients carrying a t(1;14) translocation.
July-August 2019Volume 16, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology